Topical Erythropoietin Promotes Wound Repair in Diabetic Rats  by Hamed, Saher et al.
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Wound healing in diabetic patients is slower than in healthy individuals. Erythropoietin (EPO) has non-
hemopoietic targets in the skin, and systemically administered EPO promotes wound healing in experimental
animals. This study investigated the effect of topical EPO treatment on defective wound repair in the skin of
diabetic rats. Full-thickness excisional skin wounds were made in 38 rats, of which 30 had diabetes. The wounds
were then treated topically with a cream that contained either vehicle, 600 IUml1 EPO (low dose), or
3,000 IUml1 (high dose) EPO. We assessed the rate of wound closure during the 12-day treatment period, and
microvascular density (MVD), vascular endothelial growth factor (VEGF), and hydroxyproline (HP) contents, and
the extent of apoptosis in wound tissues at the end of the 12-day treatment period. Topical EPO treatment
significantly reduced the time to final wound closure. This increased rate of closure of the two EPO-treated
wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of
apoptosis. In light of our finding that topical EPO treatment promotes skin wound repair in diabetic rats, we
propose that topical EPO treatment is a therapeutically beneficial method of treating chronic diabetic wounds.
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INTRODUCTION
Normal wound healing of damaged skin is a serial process of
well recognized and predictable events, in which there are
four distinct overlapping phases: hemostasis, inflammation,
proliferation, and remodeling (Stadelmann et al., 1998;
Quinn, 1998). Interplay between blood cells, endothelial
cells, fibroblasts, and keratinocytes, and the local release of
growth factors and cytokines influences the rate of skin
wound repair. Any disruption in this interplay delays this
process (Clark, 1985; Brown et al., 1992; Shukla et al., 1998).
In diabetes mellitus, the rate of wound repair is slow
(Mustoe, 2004). The underlying mechanisms of defective
wound repair in diabetic patients are not completely under-
stood, but it is thought that all phases of the healing process
are disrupted. Indeed, delayed collagen synthesis, impaired
epithelialization, and reduced angiogenesis have been
described during the proliferative phase of the healing
process (Snyder, 2005). Others have reported that fibroblasts
do not produce adequate amounts of extracellular matrix,
and the keratinocytes do not re-epithelialize the wound
(Mansbridge et al., 1999). As a result, the skin microvascu-
lature becomes damaged, tissue ischemia ensues, and
chronic diabetic wounds develop (Stadelmann et al., 1998;
Brem et al., 2000; Sheetz and King, 2002).
Erythropoietin (EPO) is a glycoprotein hormone that regu-
lates the red blood cell mass by stimulating the proliferation and
differentiation of precursor cells, and inhibiting apoptosis in
erythroid cells in the bone marrow (Jelkmann, 1994; Ghezzi and
Brines, 2004; Brines and Cerami, 2006). There are also non-
hematopoietic cellular targets of EPO in skin, and the existence
of EPO receptors has been described on endothelial cells
(Anagnostou et al., 1990, 1994), macrophages (Haroon et al.,
2003), fibroblasts, mast cells, and melanocytes, and in hair
follicles (Isogai et al., 2006; Bodo et al., 2007). There is
experimental evidence that suggests that EPO has an important
function in skin wound healing. Buemi et al. (2002, 2004)
showed that systemically administered recombinant human EPO
can stimulate angiogenesis, and promote the healing of random
ischemic flaps and ischemic skin wounds in rats. Galeano et al.
(2004) reported that systemically administered EPO promoted
angiogenesis and the healing of wounds in diabetic mice. These
investigators also showed that EPO stimulated angiogenesis and
wound healing in experimental burn and incisional wounds in
normal mice (Galeano et al., 2006).
Vascular endothelial growth factor (VEGF) is a cytokine
that is produced by keratinocytes, macrophages, and fibro-
blasts (Altavilla et al., 2001). Owing to the fact that VEGF
can exert its effects at all stages in the angiogenetic cascade,
and its expression is increased in wound tissue (Galeano
and Buemi), it is considered to be an important mediator
of wound healing (Brown et al., 1992). Accordingly, we
hypothesized that applying EPO topically to wounds would
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be more efficacious than systemically administered EPO in
stimulating the release of VEGF from these cutaneous cell
types, and in promoting angiogenesis in full-thickness wound
repair of diabetic wounds. Using this as a working hypo-
thesis, we initiated a study, the aim of which was to
investigate the effect of topical EPO treatment on defective
wound repair in an excisional skin wound in a widely used
rat model of type 1 diabetes mellitus.
RESULTS
Three rats, two from the vehicle-treated diabetic group and
one rat from the high-dose EPO-treated group, died during
the treatment period. The elevated blood glucose levels in
the diabetic rats were not changed by topical treatment of
the wound using either vehicle or EPO-containing creams.
Topical treatment of the wound with the vehicle or EPO-
containing creams did not cause any changes in red blood
cell, leukocyte, and platelet counts, and in the hemoglobin
levels in the non-diabetic and diabetic rats (Table 1). The
plasma EPO concentration increased significantly only in
those rats in which the skin wounds were treated topically for
12 days using the high-dose EPO-containing cream. The EPO
concentrations in the wound tissues of diabetic rats that were
treated topically for 12 days with either of the EPO-contain-
ing creams increased significantly in a dose-dependent
manner (Table 1).
Effect of EPO on rate of wound closure
Figure 1 (panel a, b and c right) displays typical healing
responses of a skin wound that was treated topically with
vehicle- and high-dose EPO-containing creams. The rate of
closure of the vehicle-treated wounds of the diabetic rats was
slower than that of the vehicle-treated wounds of the non-
diabetic rats, and the most significant difference in rate was
detected on days 10 and 12. The area of the high-dose EPO-
treated open wound was significantly smaller than that of the
vehicle-treated wound from day 6 onward. When the areas of
the open wound in the low-dose EPO-treated and vehicle-
treated wounds were compared, a significant difference was
detected from day 10 onward. When the areas of the two
EPO-treated open wounds were compared, there were
significant differences on days 6, 8, 10, and 12 (Figure 2).
Effect of EPO on MVD
After 12 days, the microvascular density (MVD) of the vehicle-
treated wounds of diabetic rats was significantly lower than that
of the vehicle-treated wounds of non-diabetic rats. When tissues
from the vehicle-treated wounds of diabetic rats were examined
histologically, there were avascular areas, ectasic vessels with
edema and perivascular hemorrhage, and a marked reduction in
capillary ramification. The MVDs in the two EPO-treated
wounds were significantly higher than that in the vehicle-treated
wounds of diabetic rats (Figure 3c), and the effect of EPO on
MVD was dose dependent. There were well-vascularized areas
with an increased expression of CD31, and numerous endothe-
lial islets in the granulation tissue in EPO-treated wounds.
Effect of EPO on wound VEGF and hydroxyproline contents
The VEGF content in the vehicle-treated wounds in diabetic
and non-diabetic rats was not statistically different from each
other (Figure 4a). The hydroxyproline (HP) content in vehicle-
treated wound tissues of diabetic rats was significantly lower
than that of non-diabetic rats (Figure 4b). Topical treatment of
the wounds of diabetic rats with EPO-containing creams
significantly increased the tissue VEGF and HP contents in a
dose-dependent manner.
Effect of EPO on wound apoptosis and apoptotic sensitivity
The extent of apoptosis in the wounds of diabetic rats was
greater than that in the wounds of non-diabetic rats, and
Table 1. Effect of topical wound treatment on body weight, hematology, and plasma and tissue EPO concentrations
in the four experimental groups
Control non-
diabetic (N=8)
Control
diabetic (N=8)
Low-dose EPO
diabetic (N=10)
High-dose EPO
diabetic (N=9)
P-value (between
groups after
Day 0 Day 12 Day 0 Day 12 Day 0 Day 12 Day 0 Day 12 treatment)
Body weight (g) 261±10 293±121 249±10 236±141 251±11 241±141 250±10 238±121 o0.05
Blood glucose levels (mg per 100ml) 117±5.2 122±5.3 418±22 405±28 434±31 398±26 399±24 422±28 o0.05
RBC count (106 per mm3) 8.31±1.1 8.63±1.2 8.22±1.3 8.62±1.2 8.46±1.1 8.71±1.3 8.65±1.4 8.39±1.2 NS
Leukocyte count (106 per mm3) 11.1±1.2 11.0±1.2 10.4±1.1 11.4±1.3 10.9±1.0 10.8±1.1 11.0±1.1 11.7±1.4 NS
Platelet count (103 per l) 604±60 643±61 674±66 664±59 614±58 644±62 640±57 653±61 NS
Hemoglobin levels (g per 100ml) 15.4±1.6 15.9±1.8 15.1±1.7 15.5±1.9 15.7±1.7 15.8±1.9 16.0±2.0 15.4±1.8 NS
Plasma EPO concentration (mUml1) 18.2±2.0 19.5±2.1 19.1±2.3 18.2±2.2 18.6±2.1 21.6±2.2 18.7±2.0 26.7±2.61 o0.05
Tissue EPO concentration (mUml1) — 0.3±0.1 — 0.2±0.1 — 63.4±7.6 — 234±14.3 o0.05
Conc., concentration; EPO, erythropoietin; N, number of rats; NS not significant; RBC, red blood cells.
1Indicates difference within the group between day 0 and day 12.
Values are presented as mean±SD.
Statistical significance is set at Po0.05.
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topical EPO treatment of the wounds decreased the extent
of apoptosis in a dose-dependent manner (Figure 5a). The
expression of Bax was significantly upregulated, whereas the
expression of Bcl-xL was significantly downregulated in the
vehicle-treated wounds of diabetic rats when compared with
those in the vehicle-treated wounds of non-diabetic rats.
a
b
c
d
e
Figure 1. Treatment of the excisional wounds by vehicle- and EPO-containing creams. (a) One of the two 9-cm2 full-thickness skin wounds that were made
surgically in two representative diabetic rats (left) is displayed. Vehicle-containing cream, and low-dose (600 IUml1) or high-dose (3,000 IUml1)
erythropoietin (EPO)-containing creams were applied topically to the wounds every second day for 12 days (middle). The wounds were then covered with a
dressing film to prevent the cream from being removed and to protect the wound during self-grooming (right). (b) A typical diabetic wound after four days of
treatment with the high-dose EPO-containing cream (A) and vehicle-containing cream (O) (left). The wounds were treated again with vehicle- and EPO-
containing creams (middle), and were then covered with a dressing film (right). (c) Three representative pairs of wounded rats after 12 days of treatment with the
high-dose EPO-containing cream (A) or vehicle-containing cream (O) (left, middle, and right). (d) Representative wounds in three different diabetic rats that were
treated with vehicle-containing cream for 12 days. (e) Representative wounds in three different diabetic rats that were treated with the high-dose EPO-containing
cream for 12 days.
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Topical EPO treatment did not inhibit the expression of
Bax, irrespective of its concentration. In contrast, Bcl-xL
was strongly upregulated in a dose-dependent manner in
EPO-treated wounds when compared with the levels in the
vehicle-treated wounds of diabetic rats (Figure 5b). The
apoptotic sensitivity of vehicle-treated diabetic wounds was
significantly higher than that of vehicle-treated wounds in
non-diabetic rats. The apoptotic sensitivities of EPO-treated
wounds were significantly lower than that of vehicle-treated
wounds of diabetic rats, and the EPO effect was dose
dependent (Figure 5c).
DISCUSSION
The main finding of our study is that topical application of
EPO to a full-thickness excisional skin wound in diabetic rats
increases the rate of wound repair in a dose-dependent
manner. Our data suggest that stimulation of VEGF-induced
angiogenesis, increased collagen deposition, and inhibition
of apoptosis are the underlying mechanisms of topical
EPO action.
In diabetes mellitus, the inability of wounds to heal is
associated with an abnormality in one or more phases of the
healing process. In our study, we observed that defective
wound repair in diabetic rats is associated with reduced
wound vascularization and collagen synthesis, and with an
increased extent of apoptosis in wound tissues. The area of
the open wound after 12 days of topical EPO treatment was
substantially smaller than that of wounds that were treated
with the vehicle-containing cream. Collagen and VEGF are
required for normal wound healing. Therefore, stimulating
their synthesis when wound repair is defective would be
beneficial for promoting wound healing. We found that the
HP and VEGF contents in EPO-treated wounds were higher
than those in vehicle-treated wounds in non-diabetic and
diabetic rats. Furthermore, these increases were associated
with enhanced capillary ramification and vascularization.
These results suggest that topically administered EPO exerts
its beneficial effects on wound healing by stimulating the
deposition of collagen and VEGF secretion.
Increased apoptosis is a common phenomenon in chronic
diabetes wounds (Rai et al., 2005). Farahani and Kloth (2008)
claimed that the rate of wound closure is associated with the
extent of apoptosis in the wound: an increased rate of wound
closure is associated with a reduced extent of apoptosis. We
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Figure 2. Time course of wound healing in rats. Vehicle-containing cream,
and low-dose (600 IUml1) and high-dose (3,000 IUml1) erythropoietin
(EPO)-containing creams were applied topically to the wounds of
non-diabetic and diabetic rats every second day for 12 days. The surface
areas of the healing wounds were measured every 2 days and compared
by one-way analysis of variance. *Po0.05, **Po0.001—significance of
the difference between the mean surface area±SD of the EPO-treated
wounds and that of the vehicle-treated wounds in diabetic rats. #Po0.05,
##Po0.001—significance of the difference between the mean surface area
of low-dose EPO and high-dose EPO-treated wounds in diabetic rats or the
mean surface area of the vehicle-treated wounds of non-diabetic diabetic
rats. 100% represents complete wound closure.
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Figure 3. Effect of erythropoietin on new blood vessels formation during
wound healing. Vehicle-containing cream, and low-dose (600 IUml1) and
high-dose (3,000 IUml1) erythropoietin (EPO)-containing creams were
applied topically to the wounds of non-diabetic and diabetic rats every
second day for 12 days. Slides were prepared from tissue samples that
were harvested on day 12 and microvascular density (MVD) was assessed.
(a) Representative micrograph of newly formed skin of a wound in a diabetic
rat after 12 days of topical treatment with the vehicle-containing cream.
(b) Representative micrograph of newly formed skin of a wound in a diabetic
rat after 12 days of topical treatment with the high-dose EPO-containing
cream. Each arrow points to a newly formed blood vessel. Bar¼100 mm.
(c) Topical EPO treatment increases MVD in a dose-dependent manner. Each
bar represents the mean MVD±SD of the pooled data from each treatment
group. *Po0.05, **Po0.001—significance of the difference between the
mean MVD in the two EPO-treated wounds and that of the vehicle-treated
wounds of diabetic rats. #Po0.05, ##Po0.05—significance of the differences
between the mean MVD of vehicle-treated wounds in non-diabetic and
diabetic rats or the MVD of the low-dose and the high-dose EPO-treated
wounds in diabetic rats, respectively.
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found that (a) the extent of apoptosis in the wounds
of diabetic rats was greater than that in the wounds of non-
diabetic rats and (b) topical EPO treatment of the wounds
decreased the extent of apoptosis in a dose-dependent
manner. We also found that the expression of the anti-
apoptotic protein, Bcl-xL, was increased and the expression of
the pro-apoptotic protein, Bax, was unchanged in EPO-
treated wounds. These findings are not surprising because
EPO has anti-apoptotic properties (Li et al., 2004) and can
inhibit apoptosis by upregulating the expressions of anti-
apoptotic protein, Bcl-xL, (Wen et al., 2002). Accordingly, we
propose that topically applied EPO increases the rate of
closure of skin wounds in diabetic rats by decreasing the
extent of apoptosis and apoptotic sensitivity in wound tissue.
The complete healing of wounds is the result of a complex
set of interactions between cellular and acellular compo-
nents, and the overall clinical experience on the use of
growth factors and other mediators to accelerate wound
healing in humans and animals has been disappointing. We
found that topical application of EPO promotes skin wound
repair in diabetic rats. This promotion was not associated
with any hematological changes, such as an increase in
circulating red blood cells and platelet counts, both of which
can act as triggers for the development of numerous adverse
effects (Eschbach et al. 1987). In the light of our finding that
topical EPO seems to be both safe and efficacious in
promoting wound repair in diabetic rats, we propose that
the next stage would be to evaluate its safety and efficacy in
diabetic patients.
Our finding that topical EPO treatment promoted wound
repair in diabetic rats is in agreement with the results of
others who reported on the beneficial effects of systemic EPO
administration on wound healing of ischemic skin wounds
(Buemi et al., 2004), diabetic wounds (Galeano et al., 2004),
and burn wounds (Galeano et al., 2006) in mice. We found
that topically applied EPO increased VEGF and HP levels.
VEGF is an endogenous stimulator of angiogenesis, and the
expression of VEGF and its receptors is upregulated during
wound healing (Brown et al., 1992; Corral et al., 1999).
Angiogenesis increases the delivery of oxygen and other
nutrients that are necessary for local collagen synthesis
(Buemi et al., 2004). Takahashi et al. (2000) have shown that
EPO can stimulate the production of collagen by activating
fibroblasts. On the basis of the results of our study, we suggest
that topical EPO exerts its beneficial effects on wounds by
inducing capillary formation, increasing VEGF and collagen
synthesis, and inhibiting apoptosis. It is possible that EPO
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Figure 4. Effect of erythropoietin on vascular endothelial growth factor
(VEGF) and hydroxyproline (HP) contents of the wound bed. Vehicle-
containing cream, and low-dose (600 IUml1) and high-dose (3,000 IUml1)
erythropoietin (EPO)-containing creams were applied topically to the
wounds of non-diabetic and diabetic rats every second day for 12 days.
(a) Each bar represents the mean VEGF level±SD in the wound tissue in
each treatment group. (b) Each bar represents the mean HP content±SD
in the wound tissue in each treatment group. *Po0.05, **Po0.001—
significance of the difference between the pooled VEGF and HP levels in
the two EPO-treated wounds and that of the vehicle-treated wounds in
diabetic rats. #Po0.05 or ##Po0.05—significance of the differences
between the pooled VEGF and HP levels of the vehicle-treated wounds
in non-diabetic and diabetic rats, or the pooled VEGF and HP levels in
low-dose and the high-dose EPO-treated wounds in diabetic rats.
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Figure 5. Effect of erythropoietin on cell apoptosis in the wound beds. (a) The extent of apoptosis is expressed as a percentage of the presence of apoptosis in
the vehicle-treated wound in non-diabetic rats. (b) Expression levels of the pro-apoptotic protein, Bax, and the anti-apoptotic protein, Bcl-xL. Each bar represents
the mean expression levels±SD of Bax (black) and Bcl-xL (white), and is displayed as the of the samples in each group. (c) Apoptotic sensitivity of wound tissues
after 12 days of treatment with vehicle-containing cream and low-dose (600 IUml1) and high-dose (3,000 IUml1) erythropoietin (EPO)-containing creams.
In each bar (c) represents the value of Bax/Bcl-xL ratio in each group. *Po0.05, **Po0.001—significance of the difference between the two EPO-treated
wounds and the vehicle-treated wounds of the diabetic rat. #Po0.05, ##Po0.001—significance of the differences of the pooled data of each study parameter
from the vehicle-treated wounds in non-diabetic and diabetic rats, or the pooled data of each study parameter from the low-dose and the high-dose EPO-treated
wounds in diabetic rats.
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may also have an indirect action on wound healing. For
example, EPO may influence blood coagulation and the
immune system. Therefore, it is unclear whether the local
EPO effects are mediated by either direct and/or indirect
stimulation of its receptors on its cutaneous cellular targets.
Therefore, further studies are needed to elucidate its exact
mode of action in healing wounds in healthy and diabetic
individuals and animals.
In conclusion, topical EPO treatment promotes wound
repair in diabetic rats. To the best of our knowledge, the
results of this study show the efficacy of topical EPO treat-
ment on wound healing in diabetic animals. On the basis of
these results, we believe that topical EPO is a therapeutically
beneficial method to treat chronic diabetic wounds.
MATERIALS AND METHODS
Animals
All experimental procedures were reviewed and approved by the
Technion Animal Care and Use Committee. A total of 38 adult male
Sprague–Dawley rats (220–250 g; 8-weeks old) were purchased from
Harlan (Jerusalem, Israel) and singly housed in cages in a room with
an artificial 12-h light/dark cycle at a constant temperature range
(24±2 1C) and relative humidity (55±10%). The rats were
acclimated for 1 week before the study and had free access to
standard laboratory chow and water. Diabetes was then induced
in 30 rats by a single 60mg kg1 intraperitoneal injection of
streptozotocin (Sigma Aldrich, St Louis, MO) (Junod et al., 1969).
At 10 days after the streptozotocin injection, the blood glucose level
in a drop of tail blood from each streptozotocin-injected rat
was measured using a glucometer (FreeStyle, Abbott Diabetes
Care, Alameda, CA). Rats were considered diabetic when their
blood glucose levels were higher than 300mg per 100ml. Eight
apparently healthy rats were used as the vehicle-treated non-diabetic
control group.
The duration of the study period was 12 days. At the beginning
and end of the study period, each rat was weighed, and a blood
sample was collected for determining the red blood cell, leukocyte,
and platelet count, and hemoglobin levels. In addition, EPO levels in
plasma and homogenates of excised wound tissues of each rat were
determined using a commercial enzyme-linked immunosorbent
assay (Quantikine IVD Erythropoietin Kit, R&D Systems, MN), in
accordance with the manufacturer’s protocol.
Full-thickness skin wound preparation and the various
treatments
Skin wounds were made in ketamine/xylazine-anesthetized non-
diabetic and diabetic rats. For the diabetic rats, these skin wounds
were made 10 days after streptozotocin administration, and the
presence of hyperglycemia was confirmed. Once anesthetized, the
dorsal skin on each side of the vertebral column of each rat was
shaved, and then cleaned before creating two 9-cm2 full-thickness
skin wounds using an aseptic technique (Figure 1a). The 30 diabetic
rats were then divided randomly into three treatment groups: (1) rats
with wounds that were treated with 1ml of cream that did not
contain EPO (vehicle-treated diabetic group); (2) rats with wounds
that were treated with 1ml cream that contained 600 IUml1 EPO
(low-dose EPO-treated group); (3) rats with wounds that were treated
with 1ml cream that contained 3,000 IUml1 EPO (high-dose
EPO-treated group). The wounds of the eight non-diabetic control
rats were treated with a cream that did not contain EPO (vehicle-
treated non-diabetic group). The wounds were then covered with a
dressing film to prevent the cream from being removed, and to
protect the wound during self-grooming. Treatments and bandaging
with the dressing film were repeated every 2 days for 12 days under
ketamine/xylazine anesthesia. The creams were prepared by a
pharmacist in accordance with the recommendations in the United
States Pharmacopoeia. EPO-containing creams were prepared by
mixing 600 IU or 3,000 IU EPO with 1 g of a powder that contained
0.20% methyl paraben and 9% laureth/isoparafin/polyacrylamide,
and then dissolved in deionized water in a final volume of 1ml.
EPO was purchased as an injection (ARANESP, Amgen AG, Zug,
Switzerland), and each injection contained 150 mgml1 or 18,000 IU
EPO. We determined that the stability of EPO in the cream was
1 month at 4 1C. Postoperative analgesics and antibiotics were not
administered because these drugs may influence the healing process
and thereby confound the interpretation of the data.
Quantitative assessment of wound healing (wound closure)
The size of the open wound was determined every 2 days on days 2,
4, 6, 8, 10, and 12 when the wounds were treated with the cream,
and the bandage was replaced. To this end, transparent paper was
placed over each wound, and the shape of the wound was drawn on
the paper. The transparent paper was then superimposed on 1-mm2
graph paper to calculate the surface area of the wound. The
percentage of wound closure was calculated using the following
formulae:
%non-closedwound area ¼ Wound area on dayX
Wound area on day zero
100
%wound closure on dayX ¼ 100%-%non-closedwound area
After measuring the area of the wound on day 12, the rats were killed
humanely with a ketamine/xylazine anesthetic overdose.
Assessment of MVD
The expression levels of CD31 antigen (PECAM-1) can be used to
assess MVD in healing wounds (Li et al., 2005). Full-skin thickness
samples of wound tissue from all the dead animals were excised
carefully from the wound using a scalpel to avoid damaging its
healing edge, fixed immediately in 10% neutral-buffered formalin,
and then embedded in paraffin. Determination of the expression
levels of CD31 antigen was performed by incubating the 5-mm-thick
sections of the paraffin-embedded specimens with a mAb against
tissue CD31 (R&D Systems), and then counterstaining them with
hematoxylin. MVD was determined in five regions of interest in each
specimen in which the CD31 antibody signal was the most intense.
The number of blood vessels was counted under a light microscope
by two investigators (YU and ZK) who were blinded to the treatment
of the rats.
Determination of the VEGF content in the wounds
Samples (100mg) of freshly excised wound tissue from each dead
rat were homogenized in phosphate-buffered saline that contained
a complete protease inhibitor cocktail (Sigma Aldrich) using an
HG-homogenizer (model HG-300; MRC, Holon, Israel). The
homogenates were then centrifuged and the supernatant was filtered.
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The VEGF content in the filtrate was determined using the
Quantikine Rat VEGF immunoassay (R&D Systems), in accordance
with the manufacturer’s protocol. Absorbance was measured in a
fluorescent microplate reader at 450 nm. The amount of VEGF was
expressed as picograms per mg of wound tissue.
Determination of the HP content in the wounds
Hydroxyproline (HP) levels were used as an indirect indicator of the
amount of collagen in the wound tissues. A 100-mg sample of freshly
excised wound tissue from each dead rat was hydrolyzed in HCl,
and then diluted with deionized water. A 2-ml aliquot of the diluted
solution was mixed with chloramines-T solution before adding
p-dimethylaminobenzaldehyde. Samples (150 ml) of each solution
were then transferred to a microtiter plate, and the absorbance
of each sample was measured in a fluorescent microplate reader
at 557 nm.
Determination of the extent of apoptosis and apoptosis
sensitivity in the wounds
Apoptotic cells become increasingly more prevalent as wounds heal
(Danielsen and Maihle, 2002), and the ratio between pro-apoptotic
and anti-apoptotic members of the Bcl-2 family can be used as a
measure of apoptotic sensitivity (Zhang and Xu, 2000; Aguirre et al.,
2004). The extent of apoptosis in all the wounds was assessed
by the TUNEL assay, using a commercial kit (ApopTag Plus
Fluorescein Kit, CHEMICON, Temecula, CA) in accordance with
the manufacturer’s protocol. All samples were processed using a
FACS Calibur analyzer (Becton Dickinson, Franklin Lakes, NJ),
and data were analyzed using the Macintosh CELLQuest software
program (Becton Dickinson). The expression levels of Bax, a
pro-apoptotic protein, and Bcl-xL were determined by western
blotting. Briefly, the samples of the excised wound tissues were
homogenized in phosphate-buffered saline that contained a com-
plete protease inhibitor cocktail using an HG-homogenizer, fol-
lowed by lysis in radioimmunoprecipitation assay buffer (R&D
Systems). A 40-mg aliquot of each protein lysate was loaded onto
SDS-PAGE and then transferred to nitrocellulose membranes.
Membranes were then incubated with monoclonal antibodies
against Bax (Clone YTH6A7) and Bcl-xL (Clone YTH2H12)
(R&D Systems), before a second incubation with a horseradish
peroxidase-conjugated IgG secondary antibody. The resultant
bands were quantified using densitometry. Apoptotic sensitivity
was determined by calculating the ratio between the mean
expression levels of Bax and Bcl-xL in each sample, and the results
are expressed in arbitrary units.
Statistical analysis of the data
Data for each study parameter from the vehicle- and EPO-treated
wound tissues for each group were then pooled, and the results are
presented as mean±standard deviation. The data showed a normal
distribution by the Kolmogorov–Smirnov test. Data from each group
were statistically analyzed by one-way analysis of variance using
a computerized statistical program (Prism version 5.0, GraphPad
Software, La Jolla, CA). Differences were considered statistically
significant when Pp0.05.
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